Amylyx Pharmaceuticals EBIT

Amylyx Pharmaceuticals (AMLX) currently reports a EBIT of $-150M as of June 2026. That compares with $-200M in the prior-year period — up 21.1% year over year. That is below the sector sector average of $-63M. Use the charts on this page to explore Amylyx Pharmaceuticals's EBIT history and peer comparisons.

Amylyx Pharmaceuticals's EBIT increased from $-200M to $-150M — a 21.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Amylyx Pharmaceuticals's EBIT of $-150M is lower than the its sector sector average of $-63M. That is roughly 146.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Amylyx Pharmaceuticals reported $-150M in EBIT as of June 2026. That compares with $-200M in the prior-year period — up 21.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-150M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-63M. From there, open related valuation or income-statement pages for Amylyx Pharmaceuticals, and consider following AMLX for alerts when major investors trade the stock.